Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Arm Bayesian Phase II Trial of Self-Applied Transcutaneous Auricular Vagus Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy

NCT07925580 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07925580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Arm Bayesian Phase II Trial of Self-Applied Transcutaneous Auricular Vagus Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy
Lead sponsor
University of Miami
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
December 30, 2029
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced peripheral neuropathy (cipn)

Arms

As registered; 1 arm.

  • Auricular Vagus Nerve (AVNS) Group ExperimentalSparrow Link (taVNS)

    Participants in this group will receive a 2-week course of daily self-applied transcutaneous auricular vagus nerve stimulation (taVNS). Participants will use a portable taVNS device at home once daily for 14 consecutive days, applying stimulation to the auricular vagus nerve according to standardized instructions provided by the study team. Each stimulation session will last approximately 60 minutes.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in Daily Chemotherapy-Induced Peripheral Neuropathy Symptom Severity Measured by Numeric Rating Scale (NRS) Baseline (Days -14 to 0), Treatment period (Day 1-14)

    Participants will complete a daily electronic diary rating the severity of their most bothersome chemotherapy-induced peripheral neuropathy (CIPN) symptom (pain, numbness/tingling, burning, pressing/squeezing, or electric shocks) during the previous 24 hours using an 11-point Numeric Rating Scale (NRS), where 0 = no symptoms and 10 = worst imaginable symptoms. The primary analysis evaluates symptom trajectories using daily observations collected during the baseline and treatment periods.

Lead sponsor's other trials

University of Miami, most recent start first.

Similar trials

Same condition (Neuralgia) and phase, most recent start first.